The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop

Transfusion ◽  
2012 ◽  
Vol 52 (6) ◽  
pp. 1363-1378 ◽  
Author(s):  
Morris A. Blajchman ◽  
Jeffrey L. Carson ◽  
John W. Eikelboom ◽  
Nancy M. Heddle ◽  
Jacques Lacroix ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Comparative Effectiveness Research ◽  
Comparative Effectiveness ◽  
Effectiveness Research ◽  
Transfusion Medicine ◽  
Blood Institute ◽  
National Heart ◽  
National Heart Lung ◽  
Institute Workshop

scholarly journals The Role of the Lung Microbiome in Health and Disease. A National Heart, Lung, and Blood Institute Workshop Report

2013 ◽  
Vol 187 (12) ◽  
pp. 1382-1387 ◽  
Author(s):  
Yvonne J. Huang ◽  
Emily S. Charlson ◽  
Ronald G. Collman ◽  
Sandra Colombini-Hatch ◽  
Fernando D. Martinez ◽  
...  
Keyword(s):  
Workshop Report ◽  
Blood Institute ◽  
Lung Microbiome ◽  
National Heart ◽  
National Heart Lung ◽  
Health And Disease ◽  
Institute Workshop

scholarly journals Implementation Research to Address the United States Health Disadvantage: Report of a National Heart, Lung, and Blood Institute Workshop

Global Heart ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. 65 ◽  
Author(s):  
Michael M. Engelgau ◽  
K.M. Venkat Narayan ◽  
Majid Ezzati ◽  
Luis A. Salicrup ◽  
Deshiree Belis ◽  
...  
Keyword(s):  
United States ◽  
Implementation Research ◽  
The United States ◽  
Blood Institute ◽  
National Heart ◽  
National Heart Lung ◽  
Institute Workshop

scholarly journals The role of data and safety monitoring boards in implementation trials: When are they justified?

2020 ◽  
Vol 4 (3) ◽  
pp. 229-232
Author(s):  
Kevin Fiscella ◽  
Mechelle Sanders ◽  
Tameir Holder ◽  
Jennifer K. Carroll ◽  
Amneris Luque ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Safety Monitoring ◽  
National Institutes Of Health ◽  
Phase Iii ◽  
Blood Institute ◽  
Phase Iii Clinical Trials ◽  
National Heart Lung ◽  
Cooperative Agreements ◽  
Monitor Data

AbstractThe National Institutes of Health requires data and safety monitoring boards (DSMBs) for all phase III clinical trials. The National Heart, Lung and Blood Institute requires DSMBs for all clinical trials involving more than one site and those involving cooperative agreements and contracts. These policies have resulted in the establishment of DSMBs for many implementation trials, with little consideration regarding the appropriateness of DSMBs and/or key adaptations needed by DSMBs to monitor data quality and participant safety. In this perspective, we review the unique features of implementation trials and reflect on key questions regarding the justification for DSMBs and their potential role and monitoring targets within implementation trials.

Randomized Controlled Trials and Comparative Effectiveness Research

2012 ◽  
Vol 30 (34) ◽  
pp. 4194-4201 ◽  
Author(s):  
Olwen M. Hahn ◽  
Richard L. Schilsky
Keyword(s):  
Health Care ◽  
Randomized Controlled Trials ◽  
Comparative Effectiveness Research ◽  
Comparative Effectiveness ◽  
Cost Effective ◽  
Health Care Research ◽  
Controlled Trials ◽  
Effectiveness Research ◽  
Randomized Controlled

Comparative effectiveness research (CER) has been promoted as a way to improve the translation gap between clinical research and everyday clinical practice as well as to deliver more cost-effective health care. CER will account for a significant portion of funding allocated by the US government for health care research. Oncology has a rich history of improving clinical outcomes and advancing research through randomized controlled trials (RCTs). In this article, we review the role of RCTs in achieving the goals of CER, with particular emphasis on the role of publicly funded clinical trials.

Sign in / Sign up

Export Citation Format

Share Document